Gene polymorphism of β-defensin-1 is associated with susceptibility to periodontitis in Japanese

Takahisa Ikuta[1], Yuji Inagaki[1], Kazuya Tanaka[2], Tsuyoshi Saito[2], Yukiko Nakajima[1], Mika Bando[1], Jun-ichi Kido[1] and Toshihiko Nagata[1]

[1]Department of Periodontology and Endodontology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan

[2]BML, Inc., Saitama, Japan

Running title: β-defensin-1 SNPs in Japanese periodontitis

To whom correspondence should be addressed:
Dr. Toshihiko NAGATA
Department of Periodontology and Endodontology,
Institute of Health Biosciences, The University of Tokushima Graduate School,
3-18-15 Kuramoto, Tokushima 770-8504, JAPAN.
TEL: 81-88-633-7343 FAX: 81-88-633-7345
E-mail: nagata@dent.tokushima-u.ac.jp

Key words: periodontitis, SNP, β-defensin-1, lactoferrin

Abstract

Background and Objective: Periodontitis is a multifactorial disease associated with genetic and environmental factors. Recent reports have shown that single-nucleotide polymorphisms (SNPs) are associated with susceptibility to common diseases such as not only diabetes and hypertension but also periodontitis. Although the oral cavity is continuously exposed to various pathogenic organisms, the oral conditions are well controlled by innate and acquired immune systems. Antimicrobial peptides (AMPs) play an important role in the innate immune system; however, the association of AMP-SNPs with periodontitis has not been fully elucidated. The aim of the present study was to investigate the relationship between AMP-SNPs and periodontitis in Japanese.

Methods: One hundred and five Japanese subjects were recruited, which included 21 patients with aggressive, 28 with severe, 13 with moderate and 22 with mild periodontitis, as well as 21 age-matched healthy controls. Genomic DNA was isolated from peripheral blood in each subject. Genotypes of four reported SNPs of β-defensin-1 and lactoferrin genes (*DEFB1*: rs1799946, rs1800972 and rs11362; and *LTF*: rs1126478) were investigated using the PCR-Invader assay. Protein levels of AMP in gingival crevicular fluid (GCF) were quantified by ELISA.

Results: Case-control studies revealed that the -44 CC genotype of *DEFB1* (rs1800972) was associated with severe chronic periodontitis (odds ratio 4.15) and with combined severe and moderate chronic periodontitis (odds ratio 4.04). No statistical differences were found in other genotypes. The β-defensin-1 concentrations in GCF were significantly lower in the subjects with the -44 CC genotype of *DEFB1* than in those without this genotype. No significant differences between GCF concentrations

of AMPs and other genotypes were detected.

Conclusion: The -44 CC genotype of the β-defensin-1 gene (*DEFB1* rs1800972) may be associated with susceptibility to chronic periodontitis in Japanese.

Introduction

Periodontitis is an inflammatory disease primarily caused by the infection of dental plaque microorganisms, followed by periodontal tissue destruction after a continuous excessive immune response. There are many factors that initiate and cause the progression of periodontitis, which include not only microbial factors but also other local and systemic factors such as age, gender, ethnicity, smoking, lifestyle, stress, heredity and systemic diseases. Thus, periodontitis is considered to be a multifactorial disease associated with genetic and environmental factors (1). Genetic factors can convey susceptibility to periodontitis and recent reports have shown that single-nucleotide polymorphisms (SNPs) are important variations among the genetic factors that underlie the host response to diseases (2, 3). In general, humans have 2 to 3 million SNPs, which correspond to 0.1% of genomic DNA. SNPs in non-coding regions can affect the regulation of gene expression, and SNPs in coding regions can change protein sequences and often give rise to different biological functions. Many basic and clinical studies have shown the relationship between SNPs and susceptibility to periodontitis (2-4). It has been reported that SNPs of interleukin (IL)-1, IL-6, IL-10, IL-17, tumor necrosis factor (TNF)-α and immunoglobulin G Fc receptors (FcγR) may be associated with the initiation and progression of periodontitis (5-10). Our collaborating studies reported that vitamin D receptor (VDR) +1056 polymorphisms are related to chronic periodontitis (11) and that α2 integrin +807 polymorphisms are related to drug-induced gingival overgrowth (12).

The oral cavity is continuously exposed to various pathogenic organisms, but oral conditions are well controlled by innate and acquired immune systems. Innate immunity functions in most species, including insects, fungi, plants and mammals, as

non-specific host defence at an early stage of microorganism challenge. Antimicrobial peptides (AMPs) play an important role in the innate immune system and more than 800 AMPs have been identified (13, 14). Many AMPs such as lysozyme, defensin, lactoferrin, histatin, cystatin and calprotectin were found in the human oral cavity, and several reports demonstrated the association between periodontitis and AMP levels in saliva, gingival tissue or gingival crevicular fluid (GCF) (15-17). We previously reported that the calprotectin level in GCF correlated with gingival index in periodontitis patients (18, 19). It is conceivable that gene polymorphisms of AMPs cause differences in the innate immune system and confer susceptibility to various infectious diseases. However, there have been few reports concerning the association of AMP-SNPs with periodontitis.

Human β-defensins are small cationic AMPs, and at least four types of β-defensin have been characterized (20). β-defensin-1 is a prominent molecule of the defensin family that is encoded by the *DEFB1* gene (21). SNPs of the *DEFB1* gene are located in coding and non-coding regions, including the 5'-untranslated region (5'-UTR) and 3'-UTR (22, 23). β-defensin-1 is expressed in keratinocytes and epithelial cells, and is found in the kidney, female reproductive tract, testis, gingival tissue, small intestine, large intestine, cornea and mammary gland (22, 24). Lactoferrin, also known as lactotransferrin, is a multifunctional metalloprotein, which is a member of the transferrin family (25). Human lactoferrin is encoded by the *LTF* gene and SNPs of the *LTF* gene have been identified in both coding and non-coding regions (26). Human lactoferrin is produced by mucosal epithelial cells and widely found in various secretory fluids, such as milk, saliva, tears, sweat and nasal secretions (25). In

addition, human lactoferrin is produced by secondary granules of neutrophils and is released in response to inflammation (27).

In this study, we analyzed the genotype distributions and allele frequencies of three *DEFB1* SNPs and one *LTF* SNP in Japanese periodontitis patients, and then we quantified the GCF concentrations of these AMPs in the subjects. Since SNPs are generally associated with ethnicity and geography, this study focused on Japanese subjects to determine the relationship between AMP-SNPs and aggressive or chronic periodontitis.

Materials and Methods

Subjects and Study Protocol

The protocol for this study was reviewed and approved by the ethics committee of human genome and gene analysis at the University of Tokushima (Approval No. H23-7). From subjects who agreed to participate in the study, written informed consent was obtained before undergoing periodontal examinations. Periodontal conditions were diagnosed according to the criteria of the 1999 International Workshop for Classification of Periodontal Diseases and Conditions (28). The subjects were divided into five groups: aggressive periodontitis (AgP), chronic periodontitis (severe CP, moderate CP and mild CP) and age-matched healthy controls, on the basis of clinical examinations including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP) and alveolar bone loss (BL). The bone loss was assessed at 2 sites of a tooth on a radiograph (29). Exclusion criteria were the presence of systemic disease (e.g., diabetes mellitus and kidney disease), drug-induced gingival overgrowth, pregnancy, having fewer than 15 teeth and a history of any periodontal therapy within the previous 6 months. In this study, age-matched healthy controls were subjects under 35 years old in the case of AgP and more than 40 years old in the case of mild CP, both having localized PD $\leq$ 3 mm and mean BL $\leq$ 15%. The AgP group consisted of subjects under 35 years old having localized CAL $\geq$ 5 mm, the severe CP group consisted of subjects more than 40 years old having localized PD $\geq$ 4 mm and mean BL $\geq$ 34%, and the moderate CP group consisted of subjects more than 40 years old having localized PD $\geq$ 4 mm and 17% $\leq$ mean BL $\leq$ 28%. One hundred and five Japanese subjects were recruited, including 21 with AgP, 28 with severe CP, 13 with moderate CP, 22 CP controls and 21 AgP controls.

Isolation of Genomic DNA and Genotype Determination

Five milliliters of peripheral blood was obtained from the basilic, cephalic or median cubital vein of each subject. Genomic DNA was isolated from the blood sample and the genotypes of the β-defensin-1 gene (*DEFB1*) and the lactoferrin gene (*LTF*) were determined using a PCR-Invader assay by BML Inc. (Saitama, Japan). The PCR-Invader assay was reported previously (30). In this study, we assayed three known SNPs in the 5'-UTR of *DEFB1*, namely, at positions -52 G/A (rs1799946; a guanine to adenine nucleotide mutation), -44 C/G (rs1800972; a cytosine to guanine nucleotide mutation) and -20 G/A (rs11362; a guanine to adenine nucleotide mutation) from the first AUG codon (31-33). In addition, we assayed one known SNP of *LTF*, namely, at position 29 in the N-terminal alpha-helical region of human lactoferrin (rs1126478; an adenine to guanine nucleotide mutation) (34, 35).

Sampling of Gingival Crevicular Fluid and β-defensin-1 Quantification

Gingival crevicular fluid (GCF) samples were collected according to a previously described method (36). Briefly, before the clinical evaluation including PD and BOP, GCF was collected using Periopaper® (Oraflow Inc., New York, NY) from healthy gingival crevices or periodontal pockets with periodontitis. GCF volume was determined using Periotron 8000® (Harco Electronics, Winnipeg, MB, Canada). The GCF perfused in paper strips was extracted using 100 μL of 10 mM Tris–HCl buffer (pH 7.4) containing 200 μM phenylmethylsulfonyl fluoride. The amounts of β-defensin-1 and lactoferrin in GCF samples were determined using enzyme-linked immunosorbent assay (ELISA) kits (Human BD-1 ELISA Kit, pink-ONE, KOMA

BOTEC Inc., Seoul, Korea; Human Lactoferrin ELISA Kit; HyCult Biotechnology b.v., Uden, Netherlands). The samples were diluted 2- or 10-fold with the dilution buffer of each kit and used for the determination of β-defensin-1 and lactoferrin according to the manufacturers' instructions. After the total amounts of β-defensin-1 and lactoferrin were measured from the standard curve, the β-defensin-1 and lactoferrin concentrations of GCF samples were obtained as pg or ng/μl by adjusting for the GCF volume.

Statistical Analyses

The distribution of each SNP genotype was evaluated for Hardy-Weinberg equilibrium. Statistical analyses were performed using JMP® software (SAS Institute Inc., Cary, NC). The differences in genotype distributions and allele frequencies were tested by chi-square tests. When an expected value in cells was less than five, Fisher's exact tests were used. Contingency tables (2 x 2) were used for three kinds of comparison: AgP *vs.* AgP control, severe CP *vs.* CP control, and combined periodontitis (severe CP and moderate CPs) *vs.* CP control. The strength of the associations was determined using odds ratio (OR) calculation and 95% confidence intervals (95% CI). In the ELISA analysis, the relationships between β-defensin-1 concentration in GCF and *DEFB1* genotypes and between lactoferrin concentration in GCF and *LTF* genotype were evaluated using the nonparametric Wilcoxon signed-rank test and Mann-Whitney *U*-test. A *p*-value of less than 0.05 was considered to be statistically significant.

Results

Demographics

Table 1 provides a summary of the demographic and clinical characteristics of the 105 Japanese subjects in the five groups, consisting of AgP, severe CP, moderate CP, CP control and AgP control. The mean ages of those with severe CP, moderate CP and CP control were similar, whereas those with AgP were significantly older than those in the AgP control group ($p<0.05$). The AgP group showed significantly higher values of BL, PPD and BOP than the AgP control. The severe CP group showed significantly higher values of BL, PPD and BOP than the CP control group. The moderate CP group showed a significantly higher value of BL than the CP control. When the severe and moderate CPs were combined (n = 41), higher values of BL, PPD and BOP were observed in the combined group than in the CP control group ($p<0.01$, data not shown).

SNP analysis of *DEFB1* and *LTF*

We analyzed three SNPs at positions -52 G/A, -44 C/G and -20 G/A in the 5'-UTR of *DEFB1* and one SNP at position 29, Lys/Arg, in the N-terminal alpha-helical region of human lactoferrin. The genotype distribution of these SNPs did not show any significant difference from Hardy-Weinberg equilibrium. The genotype distributions and allele frequencies of *DEFB1* and *LTF* polymorphisms among the five groups are summarized in Tables 2 and 3. The frequency of the -44 CC genotype of *DEFB1* was higher in the severe CP group (85.7%) and the moderate CP group (84.6%) than in the CP control (59.1%). The frequency of the -44 C allele was higher in the severe CP group (92.9%) than in the CP control (79.5%). In the case of the AgP group, no difference of -44 CC genotype or the -44 C allele was observed between AgP and its

control. These results indicate that the frequencies of the -44 CC genotype and the -44 C allele of *DEFB1* were relatively high in cases of chronic periodontitis. In this study, we performed three kinds of comparison: AgP *vs.* AgP control, severe CP *vs.* CP control, and combined periodontitis (moderate and severe CPs) *vs.* CP control for genotypic/allelic associations of the *DEFB1* and *LTF* polymorphisms. No significant differences were observed in the genotypic/allelic associations of the *DEFB1* and *LTF* polymorphisms between AgP and AgP control (Table 2). However, in the -44 C/G polymorphism of *DEFB1*, statistical significance was observed between the -44 CC genotype and severe periodontitis (OR 4.154, 95% CI 1.113–15.304, $p<0.05$) and between the -44 CC genotype and combined periodontitis (OR 4.038, 95% CI 1.236–13.186, $p<0.05$). Statistical significance was also identified between the -44 C allele and severe periodontitis (OR 3.343, 95% CI 1.003–11.041, $p<0.05$). There were no significant differences in the genotypic/allelic associations of other *DEFB1* and *LTF* SNPs for severe CP *vs.* CP control and combined periodontitis *vs.* CP control (Table 3).

GCF analysis of β-defensin-1 and lactoferrin

To evaluate the relationship between the genotype and expressions of AMPs in GCF samples, 67 GCF samples from 17 subjects and 71 GCF samples from 16 subjects were used for the determination of β-defensin-1 and lactoferrin, respectively. As shown in Fig. 1A, ELISA analysis revealed that the β-defensin-1 concentrations were significantly lower in the subjects with the -44 CC genotype than in those without the -44 CC genotype, namely, 0.95 ± 0.36 and 1.55 ± 0.63 pg/μl, respectively ($p<0.05$). Moreover, the β-defensin-1 concentrations in PD ≤ 3 mm were significantly lower in the subjects with the -44 CC genotype than in those without it, namely, 1.12 ± 0.43 and

2.20 ± 1.22 pg/μl, respectively (p<0.05, Fig. 1A). There were no significant differences in PD ≥ 4 mm between the subjects with the -44 CC genotype and those without it, with values of 0.86 ± 0.54 and 0.81 ± 0.13 pg/μl, respectively (Fig. 1A). When the concentrations of lactoferrin in GCF were evaluated, no significant differences were observed between the subjects with the GG genotype of *LTF* and those without it, with values of 7.77 ± 2.09 and 8.14 ± 4.85 ng/μl, respectively (Fig. 1B).

Discussion

In this study, we investigated the association of four AMP-SNPs with the susceptibility to periodontitis in 105 Japanese subjects. We selected three SNPs in the 5'-UTR of the *DEFB1* gene (rs1799946, rs1800972 and rs11362) and one SNP in exon 1 of the *LTF* gene (rs1126478). These SNPs have been considered to be associated with various infectious diseases. *DEFB1* gene polymorphisms were reported to be related to *Pseudomonas aeruginosa* airway colonization in cystic fibrosis, oral *Candida* carriage, lepromatous leprosy, HIV infection, *Helicobacter pylori*-induced gastritis, severe acute pancreatitis and dental caries (31, 33, 38-42). *LTF* gene polymorphism was reported to be related to dental caries (37). In terms of the SNPs in the 5'-UTR of *DEFB1*, it was reported that -44 C/G was not associated with early-onset periodontitis (43) and that -20 G/A was not associated with severe chronic periodontitis (32). In the case of *LTF*-SNP, Lys/Arg polymorphism was shown to be associated with aggressive periodontitis (34, 35). In this study, we provided the first evidence that the -44 CC genotype of *DEFB1* was associated with severe chronic periodontitis and severe/moderate-combined periodontitis (odds ratios of 4.154 and 4.038, respectively), whereas there was no association with aggressive periodontitis. This result is similar to a previous report that showed that the -44 C/G polymorphism was not associated with aggressive periodontitis (43).

The present finding that the -44 CC genotype is associated with chronic periodontitis may be linked to the low expression of β-defensin-1 in gingival tissue because basal levels of β-defensin-1 reflect a protective ability in localized tissues (44, 45). Our result suggests that the -44 C/G polymorphism may affect β-defensin-1 expression in gingival tissue and enhance the disease susceptibility to chronic periodontitis. It has

been reported that the constitutive human β-defensin-1 mRNA level was lower in primary gingival keratinocytes associated with the -44 CC genotype than in cells associated with the -44 GG and -44 GC genotypes, and that the -44 G allele was associated with an increase in constitutive antimicrobial activity and expression of β-defensin-1 (46). Recent study concerning lepromatous leprosy demonstrated that position -44 is included in the putative NFκB binding site and the variant could change the NFκB binding affinity and thus influence the regulation of *DEFB1* gene expression at the transcription stage (38). Furthermore, several reports showed the homology score between the region from positions -57 to -15 of *DEFB1* and the NFκB binding site, and the value for the -44 C allele was shown to be lower than that for the -44 G allele (homology scores of 64.5% and 69.8%, respectively), indicating that the -44 C/G polymorphism could contribute to susceptibility to infectious disease (38, 47, 48). Our finding that the subjects with the -44 CC genotype exhibited low concentrations of β-defensin-1 in GCF might be attributable to the -44 C allele being involved in a decrease in NFκB binding affinity. Since the association between -44 C/G polymorphism and NFκB binding affinity is not completely understood, further study including gel mobility shift assay might be necessary to clarify the mechanism involved. The present finding that the β-defensin-1 concentrations in localized PD ≤ 3 mm, unlike in PD ≥ 4 mm, were low in the subjects with the -44 CC genotype suggests that the -44 CC genotype may be related to the onset of chronic periodontitis. However, the subjects with the -44 CC genotype did not always suffer from chronic periodontitis because periodontitis is a multifactorial disease associated with not only genetic factors but also environmental ones.

It is generally known that β-defensins are expressed in mucosal epithelial cells and

keratinocytes in order to protect oral mucosal surfaces. β-defensin-1 was shown to be expressed constitutively in epithelial tissue, but β-defensin-2, -3 and -4 were found to be up-regulated by proinflammatory cytokines and microorganisms (16, 21). β-defensin-1, -2 and -3 were expressed in both inflamed and non-inflamed gingival tissues, whereas differential expressions were observed among tissues from healthy subjects, and cases of gingivitis and periodontitis (49-51). The level of β-defensin-1 mRNA expression was low in cases of gingivitis and aggressive periodontitis, but high in chronic periodontitis; conversely, the level of β-defensin-2 mRNA expression was high in aggressive periodontitis but low in chronic periodontitis (52). From these findings, our result may reflect that β-defensin-1 plays a role in defense of the gingival mucosal surface.

In this study, we demonstrated that the -52 G/A and -20 G/A polymorphisms of β-defensin-1 were not related to aggressive and chronic periodontitis. This result is partially consistent with a previous report (32). Although previous reports showed that the Lys/Arg polymorphism of lactoferrin was associated with aggressive periodontitis (34, 35), our result showed that there were no significant differences in the associations of Lys/Arg polymorphism with aggressive and chronic periodontitis. In addition, the concentrations of lactoferrin in GCF did not show any differences between the subjects with and without the GG genotype. It has been reported that Lys/Arg polymorphism of lactoferrin might change the protein sequence and give rise to reduced antimicrobial activity of lactoferrin (34). However, our results showed that the Lys/Arg polymorphism was not related to aggressive and chronic periodontitis in Japanese patients. We assume that these results might be due to ethnicity and geography because some reports have indicated that a Thr/Ala polymorphism at position 11

resulting from an A/G transition was associated with aggressive periodontitis in African-Americans but not in Caucasians (53).

Taken together, we conclude that the -44 CC genotype of *DEFB1* is associated with the susceptibility to chronic periodontitis in Japanese and that -44 C/G polymorphism can be a predictor of chronic periodontitis.

Conclusion

The -44 CC genotype of the β-defensin-1 gene (*DEFB1* rs1800972) may be associated with susceptibility to chronic periodontitis in Japanese.

Acknowledgments

This study was supported by a Grant-in-Aid for Scientific Research (No. 21592626) from the Japan Society for the Promotion of Science (JSPS).

References

1. Stabholz A, Soskolne WA, Shapira L. Genetic and environmental risk factors for chronic periodontitis and aggressive periodontitis. *Periodontol 2000* 2010; 53:138-53.

2. Kinane DF, Shiba H, Hart TC. The genetic basis of periodontitis. *Periodontol 2000* 2005; 39:91-117.

3. Yoshie H, Kobayashi T, Tai H, Galicia JC. The role of genetic polymorphisms in periodontitis. *Periodontol 2000* 2007; 43:102-32.

4. Suzuki A, Ji G, Numabe Y, Muramatsu M, Gomi K, Kanazashi M, Ogata Y, Shimizu E, Shibukawa Y, Ito A, Ito T, Sugaya A, Arai T, Yamada S, Deguchi S, Kamoi K. Single nucleotide polymorphisms associated with aggressive periodontitis and severe chronic periodontitis in Japanese. *Biochem Biophys Res Commun* 2004; 317:887-92.

5. Kornman KS, Crane A, Wang HY, di Giovine FS, Newman MG, Pirk FW, Wilson TG Jr, Higginbottom FL, Duff GW. The interleukin-1 genotype as a severity factor in adult periodontal disease. *J Clin Periodontol* 1997; 24:72-7.

6. Trevilatto PC, Scarel-Caminaga RM, de Brito RB Jr, de Souza AP, Line SR. Polymorphism at position -174 of IL-6 gene is associated with susceptibility to chronic periodontitis in a Caucasian Brazilian population. *J Clin Periodontol* 2003; 30:438-42.

7. Scarel-Caminaga RM, Trevilatto PC, Souza AP, Brito RB, Camargo LE, Line SR. Interleukin 10 gene promoter polymorphisms are associated with chronic periodontitis. *J Clin Periodontol* 2004; 31:443-8.

8. Kadkhodazadeh M, Baghani Z, Ebadian AR, Youssefi N, Mehdizadeh AR, Azimi N. IL-17 gene polymorphism is associated with chronic periodontitis and peri-implantitis in Iranian patients: a cross-sectional study. *Immunol Invest* 2013; 42:156-63.

9. Soga Y, Nishimura F, Ohyama H, Maeda H, Takashiba S, Murayama Y. Tumor necrosis factor-α gene (TNF-α) -1031/-863, -857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese. *J Clin Periodontol* 2003; 30:524-31.

10. Kobayashi T, Yamamoto K, Sugita N, van der Pol WL, Yasuda K, Kaneko S, van de Winkel JG, Yoshie H. The Fc γ receptor genotype as a severity factor for chronic periodontitis in Japanese patients. *J Periodontol* 2001; 72:1324-31.

11. Kobayashi T, Nagata T, Murakami S, Takashiba S, Kurihara H, Izumi Y, Numabe Y, Watanabe H, Kataoka M, Nagai A, Hayashi J, Ohyama H, Okamatsu Y, Inagaki Y, Tai H, Yoshie H. Genetic risk factors for periodontitis in a Japanese population. *J Dent Res* 2009; 88:1137-41.

12. Ogino M, Kido J, Bando M, Hayashi N, Wada C, Nagata T, Nishimura F, Soga Y, Takashiba S, Kubota T, Itagaki M, Shimada Y, Tai H, Yoshie H, Yamazaki N, Shinohara Y, Kataoka M. Alpha 2 integrin +807 polymorphism in drug-induced gingival overgrowth. *J Dent Res* 2005; 84:1183-6.

13. Kinane DF, Demuth DR, Gorr SU, Hajishengallis GN, Martin MH. Human variability in innate immunity. *Periodontol 2000* 2007; 45:14-34.

14. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. *Trends Immunol* 2009; 30:131-41.

15. Jentsch H, Sievert Y, Göcke R. Lactoferrin and other markers from gingival crevicular fluid and saliva before and after periodontal treatment. *J Clin Periodontol* 2004; 31:511-4.

16. Lu Q, Jin L, Darveau RP, Samaranayake LP. Expression of human β-defensins-1 and -2 peptides in unresolved chronic periodontitis. *J Periodontal Res* 2004; 39:221-7.

17. Tsai CC, Kao CC, Chen CC. Gingival crevicular fluid lactoferrin levels in adult periodontitis patients. *Aust Dent J* 1998; 43:40-4.

18. Nakamura T, Kido J, Kido R, Ohishi K, Yamauchi N, Kataoka M, Nagata T. The association of calprotectin level in gingival crevicular fluid with gingival index and the activities of collagenase and aspartate aminotransferase in adult periodontitis patients. *J Periodontol* 2000; 71:361-7.

19. Kido J, Nakamura T, Kido R, Ohishi K, Yamauchi N, Kataoka M, Nagata T. Calprotectin in gingival crevicular fluid correlates with clinical and biochemical markers of periodontal disease. *J Clin Periodontol* 1999; 26:653-7.

20. Diamond G, Ryan L. β-defensins: what are they really doing in the oral cavity? *Oral Dis* 2011; 17:628-35.

21. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human β-defensins. *Cell Mol Life Sci* 2006; 63:1294-313.

22. Prado-Montes de Oca E. Human β-defensin 1: a restless warrior against allergies, infections and cancer. *Int J Biochem Cell Biol* 2010; 42:800-4.

23. Dörk T, Stuhrmann M. Polymorphisms of the human β-defensin-1 gene. *Mol Cell Probes* 1998; 12:171-3.

24. Dale BA, Krisanaprakornkit S. Defensin antimicrobial peptides in the oral cavity. *J Oral Pathol Med* 2001; 30:321-7.

25. García-Montoya IA, Cendón TS, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin a multiple bioactive protein: an overview. *Biochim Biophys Acta* 2012; 1820:226-36.

26. Teng CT, Gladwell W. Single nucleotide polymorphisms (SNPs) in human lactoferrin gene. *Biochem Cell Biol* 2006; 84:381-4.

27. Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. *Cell Mol Life Sci* 2005; 62:2549-59.

28. Armitage GC. Development of a classification system for periodontal diseases and conditions. *Ann Periodontol* 1999; 4:1-6.

29. Schei O, Waerhaug J, Lovdal A, Arno A. Alveolar bone loss as related to oral hygiene and age. *J Periodontol* 1959; 30:7-16.

30. Mein CA, Barratt BJ, Dunn MG, Siegmund T, Smith AN, Esposito L, Nutland S, Stevens HE, Wilson AJ, Phillips MS, Jarvis N, Law S, de Arruda M, Todd JA. Evaluation of single nucleotide polymorphism typing with invader on PCR amplicons and its automation. *Genome Res* 2000; 10:330-43.

31. Tesse R, Cardinale F, Santostasi T, Polizzi A, Manca A, Mappa L, Iacoviello G, De Robertis F, Logrillo VP, Armenio L. Association of β-defensin-1 gene polymorphisms with *Pseudomonas aeruginosa* airway colonization in cystic fibrosis. *Genes Immun* 2008; 9:57-60.

32. Wohlfahrt JC, Wu T, Hodges JS, Hinrichs JE, Michalowicz BS. No association between selected candidate gene polymorphisms and severe chronic periodontitis. Hinrichs JE, Michalowicz BS. *J Periodontol* 2006; 77:426-36.

33. Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA. Single-nucleotide polymorphisms (SNPs) in human β-defensin 1: high-throughput SNP assays and association with *Candida* carriage in type I diabetics and nondiabetic controls. *J Clin Microbiol* 2003; 41:90-6.

34. Velliyagounder K, Kaplan JB, Furgang D, Legarda D, Diamond G, Parkin RE, Fine DH. One of two human lactoferrin variants exhibits increased antibacterial and transcriptional activation activities and is associated with localized juvenile

periodontitis. *Infect Immun* 2003; 71:6141-7.

35. Wu YM, Juo SH, Ho YP, Ho KY, Yang YH, Tsai CC. Association between lactoferrin gene polymorphisms and aggressive periodontitis among Taiwanese patients. *J Periodontal Res* 2009; 44:418-24.

36. Kido J, Nakamura T, Asahara Y, Sawa T, Kohri K, Nagata T. Osteopontin in gingival crevicular fluid. *J Periodontal Res* 2001; 36:328-33.

37. Azevedo LF, Pecharki GD, Brancher JA, Cordeiro CA Jr, Medeiros KG, Antunes AA, Arruda ES, Werneck RI, de Azevedo LR, Mazur RF, Moysés SJ, Moysés ST, Faucz FR, Trevilatto PC. Analysis of the association between lactotransferrin (*LTF*) gene polymorphism and dental caries. *J Appl Oral Sci* 2010; 18:166-70.

38. Prado-Montes de Oca E, Velarde-Félix JS, Ríos-Tostado JJ, Picos-Cárdenas VJ, Figuera LE. SNP 668C (-44) alters a NF-κB1 putative binding site in non-coding strand of human β-defensin 1 (*DEFB1*) and is associated with lepromatous leprosy. *Infect Genet Evol* 2009; 9:617-25.

39. Ricci E, Malacrida S, Zanchetta M, Montagna M, Giaquinto C, De Rossi A. Role of β-defensin-1 polymorphisms in mother-to-child transmission of HIV-1. *J Acquir Immune Defic Syndr* 2009; 51:13-9.

40. Kocsis AK, Kiss ZF, Tiszlavicz L, Tiszlavicz Z, Mándi Y. Potential role of human β-defensin 1 in *Helicobacter pylori*-induced gastritis. *Scand J Gastroenterol* 2009; 44:289-95.

41. Tiszlavicz Z, Szabolcs A, Takács T, Farkas G, Kovács-Nagy R, Szántai E, Sasvári-Székely M, Mándi Y. Polymorphisms of β defensins are associated with the risk of severe acute pancreatitis. *Pancreatology* 2010; 10:483-90.

42. Ozturk A, Famili P, Vieira AR. The antimicrobial peptide *DEFB1* is associated

with caries. *J Dent Res* 2010; 89:631-6.

43. Boniotto M, Hazbón MH, Jordan WJ, Lennon GP, Eskdale J, Alland D, Gallagher G. Novel hairpin-shaped primer assay to study the association of the -44 single-nucleotide polymorphism of the *DEFB1* gene with early-onset periodontal disease. *Clin Diagn Lab Immunol* 2004; 11:766-9.

44. Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, Tack BF, McCray PB Jr. Production of β-defensin antimicrobial peptides by the oral mucosa and salivary glands. *Infect Immun* 1999; 67:2740-5.

45. Krisanaprakornkit S, Weinberg A, Perez CN, Dale BA. Expression of the peptide antibiotic human β-defensin 1 in cultured gingival epithelial cells and gingival tissue. *Infect Immun* 1998; 66:4222-8.

46. Kalus AA, Fredericks LP, Hacker BM, Dommisch H, Presland RB, Kimball JR, Dale BA. Association of a genetic polymorphism (-44 C/G SNP) in the human *DEFB1* gene with expression and inducibility of multiple β-defensins in gingival keratinocytes. *BMC Oral Health* 2009; 9:21.

47. Naslavsky MS, Rocha CR, Lima Filho JL, Crovella S. Predicting alternative candidates as binding sites to *DEFB1* 668 (-44) SNP: a long way from statistical association with multifactorial diseases. *Infect Genet Evol* 2009; 9:1129-31.

48. Naslavsky MS, Crovella S, Lima Filho JL, Rocha CR. The sound of silence: human β-defensin-1 gene untranslated SNPs change the predicted mRNA secondary structure in a length-dependent manner. *Immunol Lett* 2010; 129:53-5.

49. Ford PJ, Gamonal J, Seymour GJ. Immunological differences and similarities between chronic periodontitis and aggressive periodontitis. *Periodontol 2000* 2010; 53:111-23.

50. Dommisch H, Açil Y, Dunsche A, Winter J, Jepsen S. Differential gene expression of human β-defensins (hBD-1, -2, -3) in inflammatory gingival diseases. *Oral Microbiol Immunol* 2005; 20:186-90.

51. Bissell J, Joly S, Johnson GK, Organ CC, Dawson D, McCray PB Jr, Guthmiller JM. Expression of β-defensins in gingival health and in periodontal disease. *J Oral Pathol Med* 2004; 33:278-85.

52. Vardar-Sengul S, Demirci T, Sen BH, Erkizan V, Kurulgan E, Baylas H. Human β defensin-1 and -2 expression in the gingiva of patients with specific periodontal diseases. *J Periodontal Res* 2007; 42:429-37.

53. Jordan WJ, Eskdale J, Lennon GP, Pestoff R, Wu L, Fine DH, Gallagher G. A non-conservative, coding single-nucleotide polymorphism in the N-terminal region of lactoferrin is associated with aggressive periodontitis in an African-American, but not a Caucasian population. *Genes Immun* 2005; 6:632-5.

Figure Legends

Figure 1. Associations between the genotypes and concentrations of antimicrobial peptides in GCF samples

GCF samples were collected using paper strips and the volumes were quantified by a calibrated unit. The contents of β-defensin-1 and lactoferrin in GCF were determined using ELISA kits. β-defensin-1 concentrations of subjects with the CC, CG and GG genotypes of rs1800972 (**A**) and lactoferrin concentrations of subjects with the GG, AG and AA genotypes of rs1126478 (**B**) are shown as the mean ± SD. $*P < 0.05$ *versus* control.

Table 1. Comparison of the demographic and clinical characteristics of the study groups

	Age (yrs)	Male/Female	Tooth number	Bone loss (%)	PPD (mm)	BOP (%)
AgP (n=21)	33.0 ± 7.9 *	7 / 14	26.6 ± 2.8	28.3 ± 15.1 **	3.3 ± 0.8 **	42.5 ± 29.6 **
AgP control (n=21)	27.8 ± 4.9	9 / 12	27.8 ± 1.4	2.1 ± 3.7	2.0 ± 0.5	5.0 ± 14.1

	Age (yrs)	Male/Female	Tooth number	Bone loss (%)	PPD (mm)	BOP (%)
severe CP (n=28)	56.2 ± 8.2	11 / 17	23.8 ± 3.4 **	43.1 ± 11.4 **	4.0 ± 1.4 **	53.8 ± 23.6 **
moderate CP (n=13)	55.3 ± 8.3	4 /9	25.8 ± 3.1	22.4 ± 3.1 **	2.6 ± 0.6	24.3 ± 17.9
CP control (n=22)	55.3 ± 8.8	8 / 14	26.2 ± 2.8	8.5 ± 4.8	2.5 ± 0.7	22.2 ± 23.6

** $p < 0.01$, * $p < 0.05$

Table 2. Genotype and allele frequencies of β-defensin-1 (*DEFB1*) and lactoferrin (*LTF*) gene polymorphisms in subjects with or without aggressive periodontitis

gene	SNP	AgP	AgP-cont	AgP vs. AgP-cont		
		n (%)	n (%)	*p*-value	OR	95% CI
DFFB1	rs1799946					
	GG	7 (33.3)	5 (23.8)	0.367	1.600	0.429 – 5.927
	GA	11 (52.4)	12 (57.1)			
	AA	3 (14.3)	4 (19.0)			
	G	25 (59.5)	22 (52.4)	0.510	1.337	0.567 – 3.150
	A	17 (40.5)	20 (47.6)			
DFFB1	rs1800972					
	CC	17 (81.0)	16 (76.2)	0.500	1.328	0.321 – 5.454
	CG	3 (14.3)	5 (23.8)			
	GG	1 (4.8)	0 (0)			
	C	37 (88.1)	37 (88.1)	0.631	1.000	0.284 – 3.524
	G	5 (11.9)	5 (11.9)			
DFFB1	rs11362					
	GG	7 (33.3)	8 (38.1)	0.747	0.813	0.236 – 2.805
	GA	9 (42.9)	9 (42.9)			
	AA	5 (23.8)	4 (19.0)			
	G	23 (54.8)	25 (59.5)	0.659	0.823	0.349 – 1.942
	A	19 (45.2)	17 (40.5)			
LTF	rs1126478					
	GG	11 (52.4)	10 (47.6)	0.758	1.210	0.367 – 3.991
	AG	6 (28.6)	7 (33.3)			
	AA	4 (19.0)	4 (19.0)			
	G	28 (66.7)	27 (64.3)	0.818	1.111	0.456 – 2.706
	A	14 (33.3)	15 (35.7)			

Table 3. Genotype associations of β-defensin-1 (*DEFB1*) and lactoferrin (*LTF*) genes with chronic periodontitis

gene	SNP	severe CP	moderate CP	CP-cont	severe CP vs. CP-cont			severe CP + moderate CP vs. CP-cont		
		n (%)	n (%)	n (%)	*p*-value	OR	95% CI	*p*-value	OR	95% CI
DFFB1	rs1799946									
	GG	9 (32.1)	4 (30.8)	11 (50.0)	0.201	0.474	0.152 – 1.473	0.154	0.464	0.163 – 1.323
	GA	15 (53.6)	7 (53.8)	8 (36.4)						
	AA	4 (14.3)	2 (15.4)	3 (13.6)						
	G	33 (58.9)	15 (57.7)	30 (68.2)	0.341	0.670	0.295 – 1.522	0.288	0.659	0.307 – 1.416
	A	23 (41.1)	11 (42.3)	14 (31.8)						
DFFB1	rs1800972									
	CC	24 (85.7)	11 (84.6)	13 (59.1)	0.035*	4.154	1.113 – 15.304	0.020*	4.038	1.236 – 13.186
	CG	4 (14.3)	1 (7.7)	9 (40.9)						
	GG	0 (0)	1 (7.7)	0 (0)						
	C	52 (92.9)	23 (88.5)	35 (79.5)	0.048*	3.343	1.003 - 11.041	0.055	2.755	0.978 – 7.752
	G	4 (7.1)	3 (11.5)	9 (20.5)						
DFFB1	rs11362									
	GG	6 (21.4)	3 (23.1)	6 (27.3)	0.631	0.727	0.206 – 2.565	0.636	0.750	0.234 – 2.388
	GA	16 (57.1)	8 (61.5)	11 (50.0)						
	AA	6 (21.4)	2 (15.4)	5 (22.7)						
	G	28 (50.0)	14 (53.8)	23 (52.3)	0.821	0.913	0.417 – 2.002	0.910	0.959	0.463 – 1.985
	A	28 (50.0)	12 (46.2)	21 (47.7)						
LTF	rs1126478									
	GG	11 (39.3)	6 (46.2)	10 (45.5)	0.661	0.776	0.254 – 2.366	0.760	0.850	0.303 – 2.376
	AG	14 (50.0)	4 (30.8)	9 (40.9)						
	AA	3 (10.7)	3 (23.1)	3 (13.6)						
	G	36 (64.3)	16 (61.5)	29 (65.9)	0.866	0.931	0.410 – 2.118	0.781	0.897	0.419 – 1.921
	A	20 (35.7)	10 (38.5)	15 (34.1)						

* $p < 0.05$

A


β-defensin-1 (pg/μl GCF)
3.5
3
2.5
2
1.5
1
0.5
0
*
*
CC (n=12; 42 sites)
CG & GG (n=5; 25 sites)
CC (n=9; 22 sites)
CG & GG (n=4; 15 sites)
CC (n=8; 20 sites)
CG & GG (n=3; 10 sites)
Gross
PD ≤ 3 mm
PD ≥ 4 mm

B


Lactoferrin (ng/μl GCF)
15
10
5
0
GG (n=5; 25 sites)
AG & AA (n=11; 46 sites)

$^{*}p < 0.05$